|  |  |
| --- | --- |
|  | **NHS Prescription Services**  Bridge House  152 Pilgrim Street  Newcastle upon Tyne  NE1 6SN  0845 850 0001  Email:[nhsbsa.prescriptionservices@nhsbsa.nhs.uk](mailto:nhsbsa.prescriptionservices@nhsbsa.nhs.uk)  Website:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  22 Apr 2024 |
|  |

VERSION 4.3.0

Dear dm+d User,

**Update to Product Pack Volme Authoring Where Both Final Reconstituted Volumes and Usable Volumes are Stated in the SmPC**

Information on how the pack size for a product requiring reconstitution (as part of the normal dispensing process) is described may vary in pharmaceutical company literature.

Where an SmPC for an oral solution or oral suspension publishes both a reconstituted volume and a usable volume, and these are different, the NHS dm+d Content Committee has made the pragmatic decision that the pack size on dm+d will be based on the published usable volume.

From 1st May 2024 for the 6 products and packs listed in the table below, the VMPPs and AMPPs in dm+d are being updated to express the new pack volumes as the ‘Usable Volumes’ in dm+d and in Part VIIIA of the Drug Tariff (for 5 of the 6 products).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **AMP** | **Current AMPP** | **Part VIIIA** | **SmPC Reconstituted Volume** | **SmPC Usable Volume** | **Additional / New VMPP & AMPP for 01/05/2024** |
| Sprycel 10 mg/mL oral suspension | 99ml | N/A | 99ml | 90ml | 90ml |
| CellCept 1g/5ml oral suspension | 175ml | Cat C | 175ml | 160-165ml | 160ml **\*** |
| VFEND 40mg/ml oral suspension | 75ml | Cat C | 75ml | 70ml | 70ml |
| Valcyte 50mg/ml oral solution | 100ml | Cat C | 100ml | 88ml | 88ml |
| Revatio 10mg/ml oral suspension | 112ml | Cat C | 112ml | 90ml | 90ml |
| Tamiflu 6mg/ml oral suspension | 65ml | Cat C | 65ml | Not stated but can be worked out as 50ml & Roche have confirmed | 50ml |
| * Where a usable volume range is presented in the SmPC then the lowest level of the usable volume will be the pack size published on dm+d. | | | | | |

If you have any further questions with respect to these changes please email [dmdenquiries@nhsbsa.nhs.uk](mailto:dmdenquiries@nhsbsa.nhs.uk)

**dm+d and SNOMED CT UK Drug Extension terminology enhancements**

The Phase 2 changes for the VMP ‘<Drug Form>’ coded attribute in dm+d are complete with the final changes in the TRUD extract Monday 18 March 2024.

To view details of all the planned changes to dm+d and SNOMED CT UK Drug Extension terminologies and the delivery timeline visit [our webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/updating-the-nhs-dm-d-drug_form-coded-attribute-within-the-vmp-concept-class) for the latest information.

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact [nhsdigital.ukmeds@nhs.net](mailto:nhsdigital.ekmeds@nhs.net).

**SNOMED International consultation on the inactivation of Role Groupers in Substance and Medicinal Product Hierarchies**

Following the [consultation](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=994809&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) SNOMED International ran up to the end of January regarding the ‘Inactivation of Role Groupers in Substance and Medicinal Product Hierarchies’, their Content Team has released their ‘Universal Summary of all feedback received’ document which can be found [here](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1047481&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136).

Under the ‘**Resolution and Next Steps**’ section of the document:

* The Substance role groupers will remain in situ with no change.
* A disclaimer will be added to the SNOMED CT Editorial Guide related to known issues with use of Substance role groupers including potential incorrect classification.
* A Briefing Note will follow regarding the inactivation of Medicinal Product therapeutic role groupers

The next step is for NHS England to circulate the Briefing Note regarding the ‘inactivation of Medicinal Product therapeutic role groupers’ and communicate next steps relating to this.

If you have any questions, please email [information.standards@nhs.net](mailto:information.standards@nhs.net)

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact [medicinestandards@nhs.net](mailto:medicinestandards@nhs.net) for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** | | | |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported | 27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported | 27/03/2023 |
| Pethidine 50mg tablets | 42161611000001107 | Imported (United States) | 14/08/2023 |
| Permethrin 5% cream | 42243511000001101 | Imported | 18/09/2023 |
| Vyvanse 30mg capsules | 42409311000001100 | Imported | 13/11/2023 |
| Vyvanse 40mg capsules | 42409611000001105 | Imported | 13/11/2023 |
| Vyvanse 50mg capsules | 42409811000001109 | Imported | 13/11/2023 |
| Vyvanse 70mg capsules | 42410011000001109 | Imported | 13/11/2023 |
| Lisdexamfetamine 30mg capsules | 42415211000001108 | Imported | 20/11/2023 |
| Lisdexamfetamine 40mg capsules | 42415411000001107 | Imported | 20/11/2023 |
| Lisdexamfetamine 50mg capsules | 42415611000001105 | Imported | 20/11/2023 |
| Lisdexamfetamine 70mg capsules | 42415811000001109 | Imported | 20/11/2023 |
| Bumetanide 5mg tablets | 42440611000001105 | Imported | 27/11/2023 |
| Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free | 42440811000001109 | Imported | 27/11/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) | 27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) | 27/11/2023 |
| Lamotrigine 5mg dispersible tablets sugar free | 41526311000001107 | Imported | 27/11/2023 |
| Rasagiline 1mg tablets | 42442211000001109 | Imported | 27/11/2023 |
| Rifampicin 150mg capsules | 42442611000001106 | Imported | 27/11/2023 |
| Dicycloverine 10mg/5ml oral solution | 42491411000001108 | Imported (United States) | 11/12/2023 |
| Diazepam 2mg/5ml oral suspension sugar free | 42495311000001104 | Special Order | 11/12/2023 |
| Hydrogen peroxide 3% solution | 42510811000001109 | Imported | 18/12/2023 |
| Lisdexamfetamine 20mg capsules | 42640311000001103 | Imported | 19/02/2024 |
| Lisdexamfetamine 60mg capsules | 42640611000001108 | Imported | 19/02/2024 |
| Methadone 5mg tablets | 42641811000001104 | Imported | 19/02/2024 |
| Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials | 42642011000001102 | Imported | 19/02/2024 |

**Invalidations**

None

**Advance Notice of Invalidations**

The following concepts will be invalidated mid-May. The reason for the invalidation is that these pack sizes were authored erroneously. Pack sizes for such concepts should not be based on bottle sizes. The dm+d Content Committee has decided that in this scenario, the most pragmatic decision is to author pack sizes based on the volumes of water to be added for reconstitution.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Rivaroxaban 1mg/ml oral suspension sugar free (VMP not being invalidated) | **VMP** No replacement but will be changing name from 1.4.24 to: Rivaroxaban 1mg/ml granules for oral suspension sugar free |
| **VMP SNOMED ID** 39609211000001101 | **VMP SNOMED ID** N/A |
| **VMPP** 250ml | **VMPP** N/A |
| **VMPP SNOMED ID** 39504911000001100 | **VMPP SNOMED ID** N/A |
| **AMP** Xarelto 1mg/ml granules for oral suspension (Bayer Plc) (AMP not being invalidated) | **AMP** N/A |
| **AMP SNOMED ID** 39505011000001100 | **AMP SNOMED ID** N/A |
| **AMPP** 100ml | **AMPP** 50ml |
| **AMPP SNOMED ID** 39505111000001104 | **AMPP SNOMED ID** 42699611000001105 |
| **AMPP** 250ml | **AMPP** 100ml |
| **AMPP SNOMED ID** 39505211000001105 | **AMPP SNOMED ID** 42699511000001106 |

dm+d Authoring Team